In this study, we further showed that treatment with CXCL5 neutralizing antibody improved the cell function in EPCs from type 2 DM patients and in HG-stimulated EPCs from non-DM subjects as well as HAECs with upregulated VEGF and SDF-1 expressions in vitro. This evidence concerns the gene CXCL5 and diabetes mellitus.